Oestrogen receptor gene overexpression – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:28:07 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Oestrogen receptor gene overexpression – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Impact of Fluoroestradiol F-18 PET on Treatment for Patients with ER+ HER2- Metastatic Breast Cancer After First-Line Hormone Therapy Relapse https://clinicaltrials.eu/trial/study-on-the-impact-of-fluoroestradiol-f-18-pet-on-treatment-for-patients-with-er-her2-metastatic-breast-cancer-after-first-line-hormone-therapy-relapse/ Wed, 29 Apr 2026 14:22:44 +0000 https://clinicaltrials.eu/trial/study-on-the-impact-of-fluoroestradiol-f-18-pet-on-treatment-for-patients-with-er-her2-metastatic-breast-cancer-after-first-line-hormone-therapy-relapse/ This clinical trial is focused on studying the impact of a special imaging technique on the treatment of patients with a specific type of breast cancer. The disease being studied is metastatic breast cancer, which means the cancer has spread to other parts of the body. The patients involved in this study have breast cancer that is estrogen receptor-positive (ER+) and HER2-negative. This means their cancer cells grow in response to the hormone estrogen but do not have an excess of the HER2 protein. The patients have experienced a return of cancer after their initial treatment, which included hormone therapy.

The treatment being tested in this study is called FLUOROESTRADIOL F-18, also known by the code name EstroTep. This is a solution that is injected into the body and used in a type of imaging called Positron Emission Tomography (PET). The purpose of the study is to see how this imaging technique can help doctors make better treatment decisions for patients whose cancer has returned after the first line of treatment. The study will involve patients undergoing a PET scan with FLUOROESTRADIOL F-18 to help guide their future treatment options.

Throughout the study, patients will receive the PET scan and their doctors will use the results to decide on the best course of treatment. This may involve changes to their current treatment plan, such as adjusting hormone therapy or adding other treatments like chemotherapy or radiotherapy. The study aims to understand how this imaging technique can improve the management of metastatic breast cancer and help doctors make more informed decisions about patient care.

]]>